This ADC product is composed of an anti-EGFR antibody conjugated via EDC/NHS linker to Dox (cetuximab-EDC/NHS-Dox). It has demonstrated a response in EGFR-positive cetuximab-resistant cancer cells treatment by a MOA (Mechanism of Action) of inhibiting Topoisomerase II and causing DNA damage.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.